ANI Pharmaceuticals (ANIP) said Monday that it expects fiscal 2024 adjusted EPS and revenue to be at or above the guidance ranges provided on Nov. 8.
ANI also said it expects fiscal 2025 revenue in the range of $739 million to $759 million. Analysts surveyed by FactSet expect $720.3 million.
Shares of the company were down 2% in recent Monday trading.
Price: 53.92, Change: -1.12, Percent Change: -2.03
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.